Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05054088 · ClinicalTrials.gov registry record
ImmuneSense COVID-19 Variant Study
A clinical trial, sponsored by Adaptive Biotechnologies.
- Completed
- Registry status
- 203
- Enrollment target
NCT05054088 is a clinical trial that has completed, run by Adaptive Biotechnologies. The registered enrollment target is 203 participants.
The verdict
NCT05054088 has completed, sponsored by Adaptive Biotechnologies.
- COMPLETED
- Registry status
- 203 participants
- Enrollment target
Study Summary
This study will assess the clinical performance of the T-Detect™ COVID test to identify an immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time of testing, including newly emerging strains of SARS-CoV-2 and their prevalence, which changes over time.
Interventions
- DEVICE T-Detect COVID test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2021-10-12 |
| Est. Completion | 2022-07-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05054088
The ClinicalTrials.gov registry entry for NCT05054088 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptive Biotechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which T-Detect COVID test is the first listed.
NCT05054088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05054088 about?
NCT05054088 is a clinical study titled "ImmuneSense COVID-19 Variant Study". This study will assess the clinical performance of the T-Detect™ COVID test to identify an immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time of testing, including new...
What is the current status of trial NCT05054088?
This trial is currently completed. The enrollment target is 203 participants. The study started on 2021-10-12. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT05054088?
The interventions under investigation include: T-Detect COVID test (DEVICE).
Who is sponsoring clinical trial NCT05054088?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.